TRx0237

DRUG3 trials

Sponsors

TauRx Therapeutics Ltd

Conditions

Alzheimer DiseaseAlzheimer's DiseaseBehavioral Variant Frontotemporal Dementia (bvFTD)

Phase 2

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

TerminatedNCT01626391

TauRx Therapeutics LtdAlzheimer's Disease

Start: 2012-09-30End: 2013-03-31Updated: 2014-07-11

Phase 3

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

CompletedNCT01626378

TauRx Therapeutics LtdBehavioral Variant Frontotemporal Dementia (bvFTD)

Start: 2013-05-31End: 2016-02-29Updated: 2018-03-14

Unknown Phase

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

TauRx Therapeutics LtdAlzheimer Disease

Updated: 2024-09-27